Takashi Matsuki

Department Of Head And Neck Surgery
Kanagawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions.

HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: May 05, 2026

Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.

Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.

Journal: Head & neck

Published: March 28, 2026

Mucous Membrane Pemphigoid during CPX-351 Therapy Successfully Treated with Corticosteroids.

Mucous Membrane Pemphigoid during CPX-351 Therapy Successfully Treated with Corticosteroids.

Journal: Internal medicine (Tokyo, Japan)

Published: January 14, 2026

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial.

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial.

Journal: Current oncology (Toronto, Ont.)

Published: December 17, 2025

Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS Status.

Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS Status.

Journal: Anticancer research

Published: December 16, 2025

Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.

Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.

Journal: Asia-Pacific journal of clinical oncology

Published: July 11, 2025

Long-Term Outcomes and Social Reintegration After Salvage Open Partial Horizontal Laryngectomy Type II/III for Radiation Failure.

Long-Term Outcomes and Social Reintegration After Salvage Open Partial Horizontal Laryngectomy Type II/III for Radiation Failure.

Journal: Head & neck

Published: March 09, 2025

Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 Variants.

Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 Variants.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: February 17, 2025

Prognostic value of FDG-PET/CT findings in mucosal melanoma of the head and neck treated with carbon ion radiotherapy.

Prognostic value of FDG-PET/CT findings in mucosal melanoma of the head and neck treated with carbon ion radiotherapy.

Journal: Annals of nuclear medicine

Published: January 30, 2025

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

Journal: Anticancer research

Published: July 17, 2024

The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy.

The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy.

Journal: Oral oncology

Published: July 06, 2024

PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.

PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.

Journal: Scientific reports

Published: April 18, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026